Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BeiGene nets $169.7mm through initial public offering

Executive Summary

Cancer drug developer BeiGene (Beijing) Co. Ltd. netted $169.7mm through its initial public offering on the Nasdaq exchange of 7.6mm American Depositary Shares (representing 98.7mm ordinary shares; includes the overallotment) at $24 per ADS. (The company originally hoped to sell 5.5mm ADSs for between $22-24 apiece.)
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies